Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL10981019 | 0.91 | NAAA (0.46) | NAAACYP2C19EPHX1GAAMAPT | |
| SCHEMBL28385625 | 0.89 | CYP2C19 (0.52) | NAAACYP2C19EPHX1HTTCYP19A1 | |
| SCHEMBL2625648 | 0.89 | CYP2C19 (0.52) | NAAACYP2C19EPHX1HTTCYP19A1 | |
| SCHEMBL3793744 | 0.89 | CYP2C19 (0.52) | NAAACYP2C19EPHX1HTTCYP19A1 | |
| SCHEMBL242453 | 0.87 | NAAA (0.42) | NAAACYP2C19EPHX1GAAMAPT | |
| Butane SCHEMBL11712725 | 0.83 | NAAA (0.56) | NAAACYP2C19EPHX1MAPTHTT | |
| Butane SCHEMBL10963745 | 0.82 | NAAA (0.57) | NAAACYP2C19EPHX1MAPTHTT | |
| Butane SCHEMBL9556223 | 0.82 | NAAA (0.40) | NAAAEPHX1GAAMAPTHTT | |
| SCHEMBL11293843 | 0.78 | GAA (0.50) | NAAACYP2C19EPHX1GAAMAPT | |
| SCHEMBL7740543 | 0.78 | GAA (0.50) | NAAACYP2C19EPHX1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290444-A | Simultaneously detecting HClO and H2S double-channel ratio type fluorescent probe | 郑州大学 | 2024-07-05 | — | — | CN | claimed |
| CN-111233880-B | Preparation method of hypochlorite fluorescent probe | 江苏大学 | 2022-08-23 | — | — | CN | claimed |
| CN-113249014-B | Deep sea anticorrosive paint and preparation method thereof | 启东海大聚龙新材料科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-113372791-A | Marine heavy-duty anticorrosive paint and preparation method thereof | 启东海大聚龙新材料科技有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-113249014-A | Deep sea anticorrosive paint and preparation method thereof | 启东海大聚龙新材料科技有限公司 | 2021-08-13 | — | — | CN | claimed |
| CN-112574205-A | Preparation method of tofacitini water hydrolysis impurities | 鲁南制药集团股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-111233880-A | Preparation method of highly sensitive hypochlorite fluorescent probe with extremely low background fluorescence | 江苏大学 | 2020-06-05 | — | — | CN | claimed |
| CN-118290444-A | Simultaneously detecting HClO and H2S double-channel ratio type fluorescent probe | 郑州大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-117800921-B | Imidazolidine diketone HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117800921-A | Imidazolidine diketone HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112574205-B | Preparation method of tofacitinib water-soluble impurities | 鲁南制药集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112574205-B | Preparation method of tofacitinib water-soluble impurities | 鲁南制药集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117430509-A | Preparation and hydrolysis method of 2-alkyl-2-propyl malonic acid diester | 湖南省湘中制药有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2103623-A2 | Novel macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1924594-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | NAAA 3554/4885CYP2C19 1733/4885LDHA 2687/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | NAAA 3554/4885CYP2C19 1733/4885LDHA 2687/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | NAAA 3254/4885CYP2C19 1193/4885LDHA 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.